SPRR2A and neoplasm: HC/pIL-12/PMet (cisplatin-hyaluronic acid-interleukin-12gene-polymetformin)micelleplexes were created by Sun et al. for tumor targeting, effectivelydelivering both the chemotherapeutic drug cisplatin (CDDP) and theimmunotherapeutic cytokine pIL-12 for chemoimmunotherapy of lung cancer.Combining CDDP and pIL-12 in micelleplexes demonstrated massive cancercell remission, including cellular shrinkage and nuclear fragmentation,indicating a potent antitumor effect in female ICR and C57 mice withlung cancer.